Folfox+Irinotecan+Chemort In Esophageal Cancer
Recruiting · Phase 2 · NCT04656041
Conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
At a glance
- Research payments reported, 2025
- $336,318
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Massachusetts General Hospital (with Ipsen)
- Tested
- FOLFOX/ nal-IRI (drug), Paclitaxel (drug), Carboplatin (drug), Proton Radiation Therapy (radiation)
- Dates
- Started 2021-06-29; completion 2027-12
- Results posted
- Not yet
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan
From ClinicalTrials.gov, last updated 2025-11-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $336,318 in research payments for this study in 2025 (4 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nataliya V. Uboha, MD Hematology & Oncology · New Haven, CT
- Theodore S. Hong, MD Radiation Oncology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Wisconsin $334,768
- Dana-Farber Cancer Institute $1,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.